Areas like pharma and food and water testing could prove growth areas for the platform as instrument sales growth slows in the clinic microbiology space.
While actual clinical implementation remains distant, MALDI imaging technology has advanced to the point where it might feasibly be applied to pathology.
With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.
The deal gives BD global distribution rights for several Bruker MALDI Biotyper products, expanding a 2010 agreement key to both firms' microbiology businesses.
The company reported total revenues of $384.9 million, up from $375.4 million for the first quarter of 2016 and above analysts' consensus estimate of $372.7 million.
Presented this week at the ECCMID annual meeting, the method uses mass spec to detect alterations to bacteria lipopolysaccharides that confer resistance.
